Chronic Myelomonocytic Leukemia

This is another type of leukemia, often seen in adults. It's a slow-growing cancer of the blood. The leukemia cells are mostly monocytes, which are a type of white blood cell. It's called 'chronic' because it usually develops slowly over time.

Condition

What people with Chronic Myelomonocytic Leukemia report

Every report comes from a Lived member, sent anonymously.

Have you tried Decitabine for Chronic Myelomonocytic Leukemia?

NameHow it went

About Chronic Myelomonocytic Leukemia

What It Is

Chronic myelomonocytic leukemia (CMML) is a rare cancer of the blood-forming cells in the bone marrow. Its defining feature is a lasting excess of monocytes, a type of white blood cell that normally helps fight infection. At the same time, the marrow often makes too few healthy red blood cells and platelets, and the cells it does make may look abnormal under a microscope. CMML sits between two families of bone marrow disorders: myelodysplastic syndromes (MDS), where the marrow fails to make enough working blood cells, and myeloproliferative neoplasms (MPN), where it makes too many. People therefore experience it in different ways. Some mainly have low blood counts, causing tiredness and breathlessness from anemia, easy bruising or bleeding, and repeated infections. Others have a high white cell count, an enlarged spleen that can cause fullness or discomfort below the left ribs, night sweats, bone pain and weight loss. Many people have no symptoms at first, and the disease is found on a routine blood test. CMML matters because it can progress over time, and in some people it turns into acute myeloid leukemia (AML), a fast-growing leukemia. Despite the similar name, it is a different disease from chronic myeloid leukemia (CML) and is treated differently. It is also separate from juvenile myelomonocytic leukemia, a rare disease of young children.

Causes & Risk Factors

CMML develops when a blood stem cell in the bone marrow acquires changes in its DNA and multiplies, passing those changes to the cells it produces. These changes are acquired during life, not inherited, and are found in nearly everyone with CMML. In most people no outside cause can be identified. Age is the main risk factor. Most people are diagnosed in their 70s, and men are affected more often than women. About 1 in 10 cases follow earlier chemotherapy or radiation for another cancer, and these tend to be harder to treat. Exposure to radiation or certain chemicals at work or in the environment may also raise risk. Having a risk factor does not mean someone caused their illness, and many people with CMML have none. Some people with CMML also have an autoimmune or inflammatory condition, either before or alongside the leukemia. This is a recognized association rather than a cause.

How It's Diagnosed

CMML is often first suspected when a complete blood count (CBC) shows a high monocyte count. For CMML, the monocyte count stays at 500 or more per microliter and makes up at least 10% of all white cells for more than three months. A single high reading is not enough, because infections, recovery from an illness and some inflammatory diseases also raise monocytes. When other explanations have been ruled out, the next step is a bone marrow aspiration and biopsy, in which a needle removes a small sample of marrow and bone, usually from the hip bone after the skin is numbed. The sample is examined for abnormal-looking cells and for blasts, the immature cells that define how advanced the disease is. Chromosome and gene tests look for changes typical of CMML and, importantly, rule out CML and a few related disorders that respond to specific targeted drugs. The results are combined into a risk score. Doctors use the blast percentage (CMML-1 has fewer blasts, CMML-2 more), the white cell count, the degree of anemia and particular gene changes, such as mutations in a gene called ASXL1, which generally point toward higher risk, to estimate how the disease is likely to behave. That score guides whether watching, medication or a transplant makes most sense.

Treatment Options

Treatment depends on the risk score, symptoms, blood counts, age and overall fitness. There is no single standard approach, and joining a clinical trial is often encouraged because current options are limited. People with lower-risk CMML and few symptoms may start with watchful waiting: regular blood tests, with treatment added if counts worsen or symptoms appear. Supportive care treats the effects of the disease. It can include red blood cell or platelet transfusions, medicines that encourage red cell production, and antibiotics or other measures to prevent infection. When the white cell count is high or the spleen is enlarged, hydroxyurea (Hydrea), an oral chemotherapy pill, is commonly used to bring counts down and ease symptoms. Hypomethylating agents are the drugs approved in the US that include CMML in their labeling: azacitidine (Vidaza), given as injections or infusions for several days each month, and decitabine, given by infusion or as a tablet combined with cedazuridine (Inqovi), which stops the body breaking decitabine down so it works when swallowed. These drugs can improve blood counts, reduce transfusion needs and lessen symptoms in roughly 40 to 50% of people, though complete remission is uncommon. Several monthly cycles are usually needed before benefit shows, and the drugs often lower blood counts further at first, so counts are checked frequently. These medicines control CMML rather than remove it, and responses usually wear off over time. An allogeneic stem cell transplant, which replaces the bone marrow with blood-forming cells from a donor, is the only treatment that can cure CMML or give long-term survival. It carries serious risks, including graft-versus-host disease (the donor cells attacking the body) and death from complications, so it is mainly considered for people with higher-risk disease who are fit enough to undergo it. Because most people are diagnosed in their 70s, only a minority are candidates.

What to Expect

CMML varies widely. Some people live for years with stable counts and few symptoms, while others have disease that progresses within months. In one widely used risk model, median survival ranged from a little over a year for the highest-risk group to about eight years for the lowest-risk group. A median is the midpoint: half the people in that group lived longer and half lived shorter. These figures come from past patients, and individual outlook depends on the details of each case and on treatment. Daily life is shaped mostly by blood counts. Anemia can make energy limited and physical effort tiring, and people who need regular transfusions spend time at the clinic. Low white cells and platelets mean taking care to avoid infections and injuries. Treatment with hypomethylating agents follows a monthly rhythm of treatment days and blood tests, and side effects such as nausea and low counts tend to cluster around those cycles. Follow-up involves regular blood tests, including checks of kidney function, and repeat bone marrow tests when the picture changes. A rising blast count or rapidly falling counts can signal progression toward AML, which changes the treatment discussion. Because options narrow if the disease progresses, many people find it helpful to talk early with their care team about goals, the role of transplant and what matters most to them.

When to Seek Help

See a doctor if a blood test shows a persistently high monocyte count, or if you have ongoing tiredness, easy bruising, unexplained weight loss, night sweats or a feeling of fullness or pain below the left ribs. If you have CMML, contact your care team at your next opportunity if you notice new bruising, minor bleeding from the gums, increasing breathlessness or fatigue, or swelling under the ribs, since these may mean your counts or spleen are changing. When platelets are low, bleeding can be harder to stop and can happen inside the body. Call your care team right away for bleeding that does not stop after a few minutes of firm pressure, black or bloody stools, vomiting blood, red or pink urine, or a bad headache, a change in vision, confusion or unusual sleepiness. If you are on treatment or have low white cell counts, call your care team right away for a fever of 100.5°F (38°C) or higher, chills or other signs of infection. Infections can become serious quickly when white cells are low. Check with your care team before taking medicine to lower a fever, since it can hide the warning sign.

Questions to Ask Your Doctor

  1. 1.Is my CMML considered lower risk or higher risk, and which test results led to that?
  2. 2.Do I need treatment now, or is watchful waiting reasonable, and what changes would make us start?
  3. 3.What could a hypomethylating agent or hydroxyurea realistically do for me, and how will we know if it is working?
  4. 4.Am I a possible candidate for a stem cell transplant, and if so, when should we start looking for a donor?
  5. 5.Are there clinical trials for CMML that I could join?

Last reviewed • Oct 2026

Educational content, not medical advice.